Sexually Transmitted Infections Among California Youth: Estimated Incidence and Direct Medical Cost, 2005 by Jerman, Petra et al.
P. Jerman et al. / Californian Journal of Health Promotion 2007, Volume 5, Issue 3, 80-91 
 
 
Sexually Transmitted Infections Among California Youth: 
Estimated Incidence and Direct Medical Cost, 2005 
 
Petra Jerman1, Norman A. Constantine1,2, Carmen R. Nevarez1
 
1Center for Research on Adolescent Health and Development, Public Health Institute 
2University of California, Berkeley 
 
Abstract 
Purpose: The purpose of this study was to estimate the incidence and the direct medical cost of sexually 
transmitted infections (STIs) among young persons in California and each of its 58 counties, and to better 
inform discussions about statewide policies and local resources needed for STI prevention and control 
efforts. Methods: On the basis of the methods developed at the Centers for Disease Control and 
Prevention we estimated the statewide number of new cases of eight major STIs among young persons 
aged 15 to 24 years in California in 2005: chlamydia, gonorrhea, syphilis, genital herpes, human 
papillomavirus (HPV), hepatitis B, trichomoniasis, and HIV. We also calculated the direct medical cost of 
these STIs using national cost-per-case estimates. To inform local policy discussions about STI control 
efforts, the statewide estimates were allocated by county. Results: An estimated 1.1 million new cases of 
STIs occurred among young persons in California in 2005, with a direct medical cost of $1.1 billion. The 
estimated number of new cases within counties ranged from a low of 82 in Alpine and Sierra counties, at 
a cost of $38,000, to a high of about 360,000 in Los Angeles County, at a cost of $390 million. 
Conclusions: These estimates illustrate the widespread and frequently underreported incidence and costs 
of youth STIs in California and its counties, and provide the foundation for a comprehensive assessment 
of youth STI prevention needs. 
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Sexually transmitted infections (STIs) can have 
considerable and long-lasting impact on the 
health and quality of life of individuals, in the 
form of infertility, ectopic pregnancies, 
dyspareunia, cancer, and increased susceptibility 
to HIV. Young persons aged 15 to 24 years 
acquire more than half of all new STIs every 
year (Weinstock, Berman, & Cates, 2004). 
National estimates show that 9.1 million new 
STIs occurred among 15-24-year-olds in the 
year 2000, the majority of which were due to 
human papillomavirus (HPV), trichomoniasis, 
and chlamydia (Weinstock, Berman, Cates, 
2004). 
 
Despite the progress over the last decade in 
screening and detecting STIs, especially among 
young persons, major obstacles remain to 
accurately monitoring the incidence and 
prevalence of STIs. Many STIs are 
asymptomatic and detected only through 
screening, not all STIs are reportable (e.g., HPV 
and trichomoniasis), and screening and reporting 
are not always complete for reportable STIs, 
which means that the true incidence of STI is 
likely to be substantially higher than the number 
of reported cases each year (California 
Department of Health Services, 2006c; Chesson, 
Blandford, Gift, Tao, & Irwin, 2004). 
 
In addition to the morbidity caused by STIs, the 
burden of STIs also is reflected in the economic 
costs associated with these infections. These 
costs comprise direct, indirect, and intangible 
costs (Chesson et al., 2004). Direct costs are 
further divided into medical and non medical 
components. Direct medical costs refer to the 
expenses of treating acute infections (e.g., 
diagnostic testing, drug treatments, and doctor 
visits) and the sequelae of untreated or 
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inadequately treated acute infections, such as 
pelvic inflammatory disease. Direct non medical 
costs are those associated with receiving medical 
treatment, such as transportation to a medical 
appointment. Indirect costs refer to productivity 
losses, or lost wages, attributable to STIs. 
Finally, intangible costs are related to the pain 
and suffering associated with STIs. 
 
The national direct medical cost of the estimated 
9.1 million cases of STIs among young persons 
aged 15 to 24 years was estimated at $6.5 billion 
for the year 2000 (Chesson et al., 2004). The 
bulk of this cost was associated with HIV and 
HPV infection. Estimates of direct nonmedical, 
indirect, and intangible costs either do not exist 
or have not been calculated for all STIs or age-
specific groups. 
 
National estimates of incidence and costs of 
STIs among young persons are important for 
national policy development and funding 
decisions on efforts to prevent STIs (Weinstock 
et al., 2004). National estimates, however, have 
limited value for states’ and counties’ policy, 
program, and budgetary decisions, as different 
states have different population profiles for STI 
risk. The purpose of this study was to estimate 
the incidence and direct medical cost of STIs 
among young persons for California and each of 
its 58 counties, extending the national estimates 
and the methodology developed by Weinstock et 
al. (2004) and Chesson et al. (2004). The 
estimated incidence and direct medical cost can 
be used to inform discussions about statewide 
policies and local resources needed for STI 




Basing our methods on those developed by 
Weinstock et al. (2004) for their national study, 
we estimated the incidence of eight major STI 
among young persons aged 15 to 24 years in 
California in 2005: chlamydia, gonorrhea, 
syphilis, genital herpes, HPV, hepatitis B, 
trichomoniasis, and HIV.  
 
Because county-specific numbers of STIs are 
not available for most STIs, we extrapolated the 
California estimates for chlamydia, gonorrhea, 
syphilis, genital herpes, HPV, hepatitis B, and 
trichomoniasis to the county level using the 
number of gonorrhea and chlamydia cases 
reported in 2005 in California (California 
Department of Health Services, 2006d), which 
are available at the county level. For both 
chlamydia and gonorrhea among 15-24-year-
olds, we calculated the proportion of each 
county’s cases from the statewide total. We then 
averaged the chlamydia and the gonorrhea 
proportion to obtain an overall proportion for 
each county. This was then multiplied by the 
statewide estimate for each STI to obtain 
county-level estimates for each STI. Given the 
limited data available on other proxies for risk at 
the county level, we assumed that the 
distributions of other STIs are associated with 
the distribution of gonorrhea and chlamydia. 
Because the distribution of chlamydia and 
gonorrhea differs slightly, and because it is 
unknown which of the two the other diseases 
follow most closely, we weighted equally the 
gonorrhea and chlamydia distributions.  
 
County-specific numbers of HIV infection also 
are not available, and thus, we used a similar 
method to extrapolate the statewide estimate for 
HIV to the county level. HIV infection is 
unlikely to follow the distribution of gonorrhea 
and chlamydia, however, so we instead used the 
number of reported sexually transmitted AIDS 
cases in each county during 2001-2005 
(California Department of Health Services, 
2006b). We assumed a minimum of one case of 
AIDS in counties for which data were withheld 
due to the small number of cases reported. We 
then calculated the proportion of each county’s 
sexually transmitted AIDS cases from the 
statewide total of sexually transmitted AIDS 
cases. The proportion for each county was 
multiplied by the statewide estimated number of 
HIV cases to obtain county-level estimates. 
 
Chlamydia 
To estimate the true incidence of chlamydia 
among young persons aged 15 to 24 years, we 
followed the method of Groseclose, Zaidi, 
DeLisle, Levine, and Louis (1996) and 
Weinstock et al. (2004). We first used data from 
the 2002 National Survey of Family Growth 
(NSFG; Centers for Disease Control and 
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Prevention, 2006a) to estimate the percentage of 
sexually active U.S. women aged 15 to 24 years 
in ethnic or racial groups (i.e., Black, White, 
Hispanic, and other). We estimated the 
percentages separately for each year of age to 
account for age differences in sexual activity. 
We then applied these percentages to the 
California Department of Finance’s (2007) 2005 
population estimates for females aged 15 to 24 
years, thus obtaining the number of 15-24-year-
old women who are sexually active and thus at 
risk for STIs. 
 
We then used California-specific chlamydia 
prevalence-monitoring data for 2005 from the 
Region IX Infertility Prevention Project 
(California Department of Health Services, 
2006e) to determine the percentage of women 
who screened positive for a chlamydial infection 
in family planning clinics. Using the number of 
sexually active women and the percentage of 
women who were positive for a chlamydial 
infection we calculated the number of prevalent 
infections for Black, White, Hispanic, and other 
women. Assuming that the duration of 
chlamydial infection in women is 0.96 years and 
that incidence of infection is its prevalence 
divided by duration (Chesson et al., 2004; 
Groseclose et al., 1999), we calculated the 
number of incident infections among women. To 
calculate the number of incident cases among 
men we assumed that the incidence among men 
equals that among women (Chesson et al., 2004; 
Groseclose et al., 1999). 
 
Gonorrhea 
To estimate the true incidence of gonorrhea 
among young persons aged 15 to 24 years in 
California we assumed that the cases reported to 
the California Department of Health Services 
(2006d) for this group in 2005 were 
underreported and under diagnosed by 50% 
(Weinstock et al., 2004). We estimated the 




We assumed that the cases of primary, 
secondary, and early latent syphilis reported to 
the California Department of Health Services 
(2005c) for young persons aged 15 to 24 years in 
2005 were underreported and underdiagnosed by 
20% (Weinstock et al., 2004). We estimated the 




Genital herpes is not a reportable STI in 
California, and no reliable state or local 
estimates of incidence exist. The herpes simplex 
virus type 2 (HSV-2) is the cause of most genital 
herpes. Weinstock et al. (2004) estimated that 
640,000 new HSV-2 infections occurred among 
young persons in the United States in the 2000. 
This estimate was based on the assumption that 
the rate of genital herpes in 2000 had remained 
the same as the rate in 1985 (Weinstock et al., 
2004). A recent study on the trends of herpes 
simplex virus type 1 and type 2 seroprevalence 
in the United States has shown, however, that 
the overall age-adjusted HSV-2 seroprevalence 
decreased by 19% between 1988–1994 and 
1999–2004 (Xu et al., 2006). 
 
Taking this decrease into consideration, we 
estimated 520,000 new HSV-2 infections among 
persons aged 15 to 24 years in the United States. 
(Gender-specific estimates were not available.) 
We then extrapolated the national estimate to 
California using a multiplier of 12.91%, which 
represents California’s proportional share of 
youth aged 15 to 24 years in the United States 
population. The multiplier was calculated using 
U.S. population estimates from the U.S. Census 
Bureau (2006) and California population 
estimates from the California Department of 
Finance (2007). This multiplier was chosen as a 
straightforward way to estimate how many of 
the national cases of genital herpes would occur 
in California based on the percentage of the U.S. 
population of young persons who live in 
California.  
 
 Human Papillomavirus (HPV) 
HPV is not a reportable STI in California, and 
no reliable state or local incidence estimates 
exist. The national incidence estimate for HPV 
(4.6 million) calculated by Weinstock et al. 
(2004) was therefore extrapolated to California 
using the multiplier of 12.91%. In estimating the 
incidence of HPV among 15–24-year-olds, 
Weinstock et al. (2004) assumed that incidence 
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To estimate the true incidence of hepatitis B 
among young persons aged 15 to 24 years, we 
followed the calculation method of Weinstock et 
al. (2004). The Centers for Disease Control and 
Prevention has estimated that 8,000 new 
infections with the hepatitis B virus occurred in 
the United States in 2004 among 15–24-year-
olds (A. Wasley, Centers for Disease Control 
and Prevention, Division of Viral Hepatitis, 
personal communication, August 1, 2006). We 
assumed that approximately half of these 
infections occurred among individuals who 
reported high-risk sexual activity (Weinstock et 
al., 2004). (Gender-specific estimates were not 
available.) We extrapolated the national 




For trichomoniasis, we extrapolated the national 
estimate (1.9 million) calculated by Weinstock 
et al. (2004) to California using the multiplier of 
12.91%. Weinstock et al. (2004) assumed that 
7.4 million new cases of trichomoniasis occurred 
in the United States in the year 2000. We 
assumed that the incidence remained the same in 
2005. Furthermore, as did Weinstock et al. 
(2004), we assumed that 25% of new infections 
occurred in 15–24-year-olds. (Gender-specific 
estimates were not available.) 
 
 Human Immunodeficiency Virus 
(HIV) 
The Office of AIDS at the California 
Department of Health Services has estimated 
there are between 6,788 and 8,988 incident cases 
of HIV in California each year (Facer, Ritieni, 
Marino, Grasso, & Social Light Consulting 
Group, 2001). Taking the midpoint of this range 
(7,888) and assuming that 75% of infections are 
acquired sexually and that 50% of sexually 
acquired HIV infections are contracted by 
individuals younger than 25 years (Weinstock et 
al., 2004), we estimated the number of new HIV 
infections among 15-24-year-olds in California. 
(Gender-specific estimates were not available.) 
 
Cost 
Using the cost-per-case estimates developed by 
Chesson et al. (2004) we calculated the direct 
medical cost of chlamydia, gonorrhea, syphilis, 
genital herpes, HPV, hepatitis B, and 
trichomoniasis for young persons aged 15 to 24 
years in California. When gender-specific data 
were available and when costs differed 
considerably between genders, Chesson et al. 
(2004) calculated gender-specific cost-per-case 
estimates, resulting in gender-specific estimates 
for chlamydia, gonorrhea, genital herpes, and 
HPV. Furthermore, using gender-neutral cost-
per-case estimates developed by Hutchinson et 
al. (2006), we also calculated the direct medical 
cost of HIV for young persons aged 15 to 24 
years in California. 
 
All estimated costs are the lifetime costs of new 
cases of STIs occurring among young persons 
aged 15 to 24 years during the year 2005 (i.e., 
incidence costs), rather than the total cost in 
2005 of existing cases of STIs and their sequelae 
among individuals who were 15 to 24 years old 
at the time of infection (i.e., prevalence costs; 
Chesson et al., 2004). Both Chesson et al. (2004) 
and Hutchinson et al. (2006) used a 3% annual 
discount rate in their calculation of all lifetime 
costs. We adjusted all costs for inflation to year 
2005 dollars using the medical care component 
of the consumer price index (Economic Report 
of the President, 2006).  
 
To calculate the total direct medical cost for 
each STI, we multiplied the inflation-adjusted 
cost per case by the estimated total number of 
incident cases of each STI estimated to have 
occurred in 2005 among young persons aged 15 
to 24 years. For the STIs for which a gender-
specific cost per case was available, we 
multiplied the gender-specific cost per case by 
the gender-specific incidence estimate or we 
assumed a male-to-female ratio in a gender-




Table 1 shows that young persons aged 15 to 24 
years in California acquired 1.1 million new 
cases of eight major STIs in the year 2005. 
Estimates for individual STIs range from more 
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than a half million new HPV cases and a quarter 
million new trichomoniasis cases, down to 380 
new syphilis cases and 520 new hepatitis B 
cases. For contrast, the table also includes the 
number of newly reported cases in California in 
2005, for those five STIs for which data are 
collected (C. Woodfil , California Department of 
Health Services, Immunization Branch, personal 
communication, January 13, 2007; California 
Department of Health Services, 2006a, 2006d). 
As can be observed, the estimated number of 
cases is higher than is the reported number of 
cases for all five reportable STIs.  
 
Table 1 also shows the average lifetime cost per 
case of each STIs, in year 2005 dollars. 
Employing the methods and assumptions 
detailed in the Methods section, we estimated 
the total statewide direct medical cost for STIs 




Reported and Estimated Number of New Cases Among 15–24-Year-Olds, Average Lifetime Cost per 




of New Cases 
in 2005 
Estimated no. of 
New Cases in 2005a Average Lifetime Cost Per Case ($) 
Total Direct 
Medical Cost ($)a
302 (females) Chlamydia 84,186 180,000 
25 (males) 
29 million 
330 (females) Gonorrhea 16,788 33,000 
66 (males) 
7.5 million 
Syphilis 313 380 550  0.2 million 
HIV 516 2,900 190,797  560 million 
Hepatitis B 41 520 965  0.5 million 
517 (females) Genital herpes – 67,000 
633 (males) 
38 million 
1,522 (females) HPV – 590,000 
33 (males) 
460 million 
Trichomoniasis – 250,000 22  5.3 million 
Total – 1.1 million NA 1.1 billion 
Note. Dashes indicate non reportable STI. NA indicates not applicable. aRounded to two significant digits. In calculating total 
direct medical costs, we assumed that males accounted for 43% of new cases of genital herpes and 50% of new HPV infections 
among 15-24-year-olds. Furthermore, gender-specific incidence estimates indicated that males accounted for 50% of new cases 





Appendix A shows the estimated number of new 
cases of STIs in 2005 and the total direct 
medical cost for each California county. The 
estimated number of new cases within counties 
ranged from a low of 82 in Alpine and Sierra, at 
a cost of $38,000, to a high of about 360,000 in 
Los Angeles county, at a cost of $390 million. 
To illustrate regional variability, the data were 
organized into five social-geographic regions 
consisting of contiguous groups of counties 
organized by geographic and demographic 
proximity (North/Mountains, Central Valley, 
Bay Area/Central Coast, Los Angeles County, 
and South). The direct medical cost ranged from 
a low $22 million in the North/Mountains region 
to $150 million and over in all other regions. 
The Los Angeles County region had the highest 
cost, at $390 million. 
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Discussion 
The most commonly used marker for the impact 
of STIs is the number of cases reported to local 
health departments. As was reinforced by our 
analysis, however, the reported number of cases 
of newly acquired STIs considerably 
underestimates their true incidence. This 
undercounting is most likely due to incomplete 
screening coverage of at-risk populations, 
underreporting of infections by medical and 
laboratory providers, and presumptively treated 
infections that are not confirmed by testing 
(California Department of Health Services, 
2006c). 
 
Furthermore, as was shown by our analysis, the 
cost of treating acute infections and their 
sequelae can be considerable, whether due to the 
high cost per case of some STIs, such as HIV, or 
due to the high incidence of other STIs, such as 
HPV. The high lifetime cost of HIV infection is 
well-known; however, the lifetime cost of other 
STIs is less well documented. The cost estimates 
from this analysis represent only a portion of the 
total economic burden of STIs among young 
people in California, as not all STIs were 
considered and direct non medical, indirect, and 
intangible costs were not estimated. 
Nevertheless, the estimates derived from this 
analysis suggest that the economic burden of 
newly acquired STIs in 2005 among young 
people in California exceeded $1 billion in direct 
medical cost. 
 
The wide range of incidence and cost estimates 
across counties results from county variations in 
STI incidence rates, together with county 
variations in the size of the 15-24-year-old age 
cohorts. Some of the major factors contributing 
to differences in STI incidence rates include 
variations in poverty levels; differences in 
sexual practices and social-sexual networks 
between urban, rural, and suburban populations; 
variations in the proportion of racial or ethnic 
populations in different counties; and differing 
levels of access to care (Aral & Holmes, 1999; 
California Department of Health Services, 
2006c; Centers for Disease Control and 
Prevention, 2006b, 2007; Sapolsky, 2005). 
 
Although non reportable infections account for a 
majority of the cost of STIs other than HIV, the 
incidence and cost of these non reportable 
infections have been largely absent from 
discussions about policy and funding at the state 
and local level in California. Here, and in most 
other states, STI prevention and control efforts 
have focused on reportable bacterial infections 
(Chlamydia, gonorrhea, and syphilis) that can be 
easily diagnosed and treated. Yet, our estimates 
show that these three STIs account for less than 
20% of the calculated incidence for all STIs 
among 15-24-year-olds in 2005 and less than 7% 
of the direct medical cost for all STIs (other than 
HIV) for this age group. Given the substantial 
incidence and costs associated with non 
reportable STIs, greater emphasis is needed on 
primary prevention, as well as monitoring, of 
these “hidden” STIs among youth, as well as all 
other age groups. Nevertheless, obstacles exists 
to preventing and monitoring non reportable 
STIs such as genital herpes, as no proven 
programs exist for preventing it, and vaccine 
trials are incomplete. In addition, mass 
screenings and using antiviral medications for 
everyone who is infected would be expensive. 
 
It is well-known that several STIs, such as non 
reportable trichomoniasis and genital herpes, 
increase the risks of transmitting and acquiring 
HIV (Centers for Disease Control and 
Prevention, 1998; McClelland et al., 2007; 
Serwadda et al., 2003; Wald & Link, 2002; 
Wasserheit, 1992). Historically, little emphasis 
has been placed on prevention and control of 
non-reportable STIs in HIV prevention efforts. 
Our incidence estimates show that genital herpes 
and trichomoniasis account for 50% more 
infections than do Chlamydia, gonorrhea, and 
syphilis combined. Thus, these two non 
reportable STIs should be included in cost-
savings calculations and in policy and program 
dialogue about STI/HIV prevention and control 
efforts in California. 
 
We relied on various assumptions in our 
calculations of incidence and cost estimates. 
Therefore, the estimates we have derived should 
be considered approximations. Our analyses are 
subject to the same limitations as were the 
methods and cost-per-case estimates on which 
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we relied in our calculations. For example, the 
assumptions included rates of underreporting, 
proportion of STIs among young people, 
treatment guidelines, previous cost estimates, 
non exhaustive direct medical costs, and others. 
In addition, although estimates of the cost 
burden of HPV-related health outcomes can vary 
substantially (Insinga, Dasbach, & Elbasha, 
2005), it is important to note that many possible 
adverse health outcomes attributable to HPV, 
such as anal, vaginal, and vulvar cancers, were 
not included in the HPV cost estimated by 
Chesson et al. (2004). Further discussion of 
these limitations can be found in the studies 
cited in the Methods section.  
 
In our calculation of the incidence of Chlamydia 
we used the 2002 NSFG (Centers for Disease 
Control and Prevention, 2006a) to estimate the 
number of sexually active women who are at 
risk for acquiring STIs. The 2002 NSFG does 
not include anal sex in its question about sexual 
activity and number of partners; therefore, any 
females who reported only anal sex in the past 
year would not be counted, but are still at risk 
for STI transmission. We relied on NSFG data in 
our calculations because California lacks reliable 
data on adolescent sexual behaviors at the 
county level and at the local school-district 
level. A coordinated, representative, statewide 
system for collecting local-level data on 
adolescent sexual behavior via standardized 
questions compatible with those used in national 
surveys of adolescents would facilitate future 
estimates.  
 
California has a robust surveillance system for 
reportable STIs, including prevalence-
monitoring projects in family planning clinics. 
These data were used in our calculation of the 
incidence of chlamydia and gonorrhea and in our 
distribution of state-level estimates to the county 
level. Nevertheless, sentinel family planning 
sites, the source of the chlamydia prevalence-
monitoring data,  are not a random sample of all 
family planning providers across California, 
clinics that participate in the prevalence 
monitoring project might not collect data on 
every person being tested, and some young 
women might not access care at family planning 
clinics, all of which could lead to either 
underestimation or overestimation of the true 
prevalence of Chlamydia in the population of 
young women in California. 
 
The methodology used to distribute the 
statewide estimated number of incident STIs 
among the counties also has limitations. Because 
the true geographic distribution of non 
reportable STIs is unknown, we used the 
distribution of reported gonorrhea and 
Chlamydia cases to approximate the distribution 
of the other STIs, except HIV. The distribution 
of reported gonorrhea and Chlamydia cases is 
largely determined by the population size of 
each county, the age and race/ethnic distribution, 
and the distribution of risk factors. Because 
population size is the main determinant of the 
STI distribution, and because the risk and 
demographic factors associated with gonorrhea 
and Chlamydia are correlated with other STIs, 
this approach is not unreasonable. Nevertheless, 
because the risk factors for different STIs are not 
perfectly correlated, and the distributions of 
different STIs are known to differ 
geographically (California Department of Health 
Services, 2006c; Centers for Disease Control 
and Prevention, 2006b), some error in the 
distribution of the estimated STIs between 
counties is introduced by this approach. 
 
Although all incidence and cost estimates 
reported here are approximate, these estimates 
provide a useful starting point for the first 
comprehensive appraisal of the costs of STIs 
among young persons in California, and for the 
allocation of this economic burden among 
counties and regions of the state. With this new 
information state and county policymakers will 
be better able to assess the sufficiency of current 
state and local resources and investments to 
prevent STIs among young persons.  
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Estimated Number of New Cases and Total Direct Medical Cost of Eight Main STIs 






Estimated no. of 
new cases in 2005 
Total direct medical 
cost($) 
North/Mountains  327,702 32,270 $21,601,000 
 Alpine 204 82 $38,000 
 Amador 5,525 451 $210,000 
 Butte 41,963 5,109 $3,600,000 
 Calaveras 6,102 448 $230,000 
 Colusa 3,858 184 $90,000 
 Del Norte 4,555 228 $110,000 
 El Dorado 25,745 1,323 $1,200,000 
 Glenn 4,860 540 $270,000 
 Humboldt 23,076 2,017 $1,800,000 
 Inyo 2,805 194 $93,000 
 Lake 8,621 1,070 $1,000,000 
 Lassen 6,578 544 $260,000 
 Mendocino 13,972 1,206 $1,100,000 
 Modoc 1,524 173 $83,000 
 Mono 1,818 114 $55,000 
 Nevada 15,584 879 $520,000 
 Placer 41,268 3,708 $2,600,000 
 Plumas 3,126 179 $87,000 
 Shasta 28,914 3,199 $1,900,000 
 Sierra 545 82 $38,000 
 Siskiyou 6,966 559 $280,000 
 Sutter 14,129 2,294 $1,200,000 
 Tehama 9,794 1,055 $580,000 
 Trinity 2,020 121 $57,000 
 Yolo 43,483 3,911 $2,800,000 
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Appendix A (continued) 
 
Estimated Number of New Cases and Total Direct Medical Cost of Eight Main STIs  








Estimated no. of new 
cases in 2005 
Direct medical 
cost ($)a
Central Valley  867,131 247,867 $163,950,000 
 Fresno 158,091 45,768 $29,000,000 
 Kern 125,000 40,830 $29,000,000 
 Kings 23,716 5,884 $4,000,000 
 Madera 22,375 4,159 $2,600,000 
 Mariposa 2,488 231 $110,000 
 Merced 46,240 9,144 $5,400,000 
 Sacramento 208,771 77,013 $52,000,000 
 San Joaquin 114,198 27,407 $19,000,000 
 Stanislaus 86,106 20,758 $13,000,000 
 Tulare 72,211 16,147 $9,500,000 
 Tuolumne 7,935 526 $340,000 
Central Coast  1,247,436 224,304 $268,540,000 
 Alameda 205,764 62,417 $58,000,000 
 Contra Costa 142,057 28,519 $24,000,000 
 Marin 27,978 2,712 $5,000,000 
 Monterey 66,691 8,494 $7,000,000 
 Napa 18,450 1,755 $1,400,000 
 San Benito 9,310 1,188 $640,000 
 San Francisco 64,300 30,116 $83,000,000 
 San Luis Obispo 47,791 3,507 $3,800,000 
 San Mateo 85,965 8,642 $11,000,000 
 Santa Barbara 71,405 7,295 $7,700,000 
 Santa Clara 219,405 34,090 $29,000,000 
 Santa Cruz 40,380 4,240 $4,100,000 
 Solano 64,920 15,440 $13,000,000 
 Sonoma 69,483 5,619 $11,000,000 
 Ventura 113,537 10,270 $9,900,000 
Los Angeles Co. Los Angeles 1,414,241 361,876 $390,000,000 
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Estimated Number of New Cases and Total Direct Medical Cost of Eight Main STIs 







15-24-year-olds Estimated no. of new cases in 2005 
Direct medical 
cost ($)a
South  1,577,704 254,794 $268,500,000 
 Imperial 28,580 2,924 $2,500,000 
 Orange 430,735 53,566 $57,000,000 
 Riverside 292,719 37,175 $49,000,000 
 San Bernardino 338,796 75,606 $50,000,000 
 San Diego 486,874 85,523 $110,000,000 
CALIFORNIA 5,434,214 1,121,111 $1,112,591,000 
Note. aCounty costs are rounded to two significant digits. To obtain the estimated number of new cases for a county, we summed 
the estimated number of new cases of each STI in that county.  
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